Compositions for the inhibition of giardia lamblia

Patent metadata

Field	Value
Publication number	US-2017216415-A1
Application number	US-201515501587-A
Country	US
Kind code	A1
Filing date	Aug 10, 2015
Priority date	Aug 8, 2014
Publication date	Aug 3, 2017
Grant date	—

Abstract

The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.

First claim

1 . Composition exhibiting a bile-salt hydrolase activity for use for the treatment or the prevention of giardiasis, wherein said composition is chosen in the group consisting of:
a composition comprising at least one bile-salt hydrolase (BSH) enzyme, a composition comprising a lactic acid bacterium able to secrete at least one BSH enzyme, with the exception of Lactobacillus johnsonii La1 , Lactobacillus acidophilus, Bifidobacterium bifidum and Bifidobacterium infantis. a composition comprising a recombinant host cell able to secrete at least one heterologous BSH enzyme, and a combination thereof, wherein said bile-salt hydrolase activity is determined by the detection of the presence of glycine or taurine liberated from conjugated bile salts, of cholic acid, of deoxycholic acid and/or of chenodeoxycholic acid.

2 . The composition for use according to claim 1 , wherein said bile-salt hydrolase activity is associated with the presence of at least one bile-salt hydrolase (BSH) enzyme.

3 . The composition for use according to claim 2 , wherein said BSH enzyme is chosen among BSH from prokaryotes, and preferably among BSH from lactic acid bacteria.

4 . The composition for use according to any one of claims 1 to 3 , wherein said BSH enzyme comprises an amino acid sequence having at least 80% identity with, or is a natural variant of, an amino acid sequence chosen in the group consisting of:
Lactobacillus johnsonii La1 BSH-12 (SEQ ID No 1), Lactobacillus johnsonii La1 BSH-47 (SEQ ID No 2), Lactobacillus johnsonii La1 BSH-56 (SEQ ID No 3),
Lactobacillus gasseri BSH-A (SEQ ID No 4), Lactobacillus gasseri BSH-B (SEQ ID No 5),
Lactobacillus johnsonii DPC 6026 BSH (SEQ ID No 6),
Lactobacillus johnsonii DPC 6026 BSH (SEQ ID No 7), and
Lactobacillus johnsonii DPC 6026 BSH (SEQ ID No 8).

5 . The composition for use according to any one of claims 1 to 4 , said composition comprising a lactic acid bacterium able to secrete a BSH, wherein said bacterium is chosen among:
Lactobacillus , with the exception of Lactobacillus johnsonii La1 and of Lactobacillus acidophilus,
Bifidobacterium , with the exception of Bifidobacterium bifidum and Bifidobacterium infantis.

6 . The composition for use according to claim 5 , wherein said lactic acid bacterium is a Lactobacillus chosen in the group consisting of:
Lactobacillus johnsonii , with the exception of Lactobacillus johnsonii La1, Lactobacillus gasseri, Lactobacillus acidophilus , with the exception of Lactobacillus acidophilus La10, and Lactobacillus reuteri.

7 . The composition for use according to claim 5 or 6 , wherein said Lactobacillus is chosen in the group consisting of the bacterial strains referenced as:
Lactobacillus johnsonii : filed at CNCM, Institut Pasteur, Paris, France, under reference I-4885, on Aug. 7, 2014
Lactobacillus gasseri : filed at CNCM, Institut Pasteur, Paris, France, under reference I-4884, on Aug. 7, 2014.

8 . A host cell for use for the treatment or the prevention of giardiasis, said host cell comprising an heterologous nucleic acid comprising at least one of the following nucleotide sequences:
nucleotide sequence encoding for L. johnsonii La1 BSH-12 (SEQ ID No 9), or a natural variant thereof, nucleotide sequence encoding for L. johnsonii La1 BSH-47 (SEQ ID No 10), or a natural variant thereof, nucleotide sequence encoding for L. johnsonii La1 BSH-56 (SEQ ID No 11), or a natural variant thereof.
wherein said host cell is able to secrete a BSH enzyme.

9 . A host cell according to claim 8 , wherein said host cell is a lactic acid bacterium.

10 . Composition for use in the treatment or the prevention of giardiasis according to any one of claims 1 to 7 , for the treatment or the prevention of giardiasis in human beings.

11 . Composition for use in the treatment or the prevention of giardiasis according to any one of claims 1 to 7 , for the treatment or the prevention of giardiasis in animals, and in particular for pigs and cows.

12 . Pharmaceutical composition comprising, as an active principle, a composition exhibiting a bile-salt hydrolase activity according to any one of claims 1 to 7 , and a pharmaceutically acceptable carrier,

13 . Food composition or dietary supplement comprising, as an active principle, a composition exhibiting a bile-salt hydrolase activity according to any one of claims 1 to 7 , and a carrier.

14 . Process for the preparation of a pharmaceutical composition according to claim 12 or for the preparation of a food composition or dietary supplement according to claim 13 , said process comprising a step of contacting a carrier and at least one of the following elements, or a combination thereof:
A bile-salt hydrolase (BSH) enzyme,
A bacterium able to secrete at least one BSH, with the exception of the bacterial strains Lactobacillus johnsonii La1 (public reference NCC533, CNCM I-1225), Lactobacillus acidophilus La10 (NCC90, CNCM I-2332), Bifidobacterium bifidum (NCC189, CNCM I-2333) and Bifidobacterium infantis (NCC200, CNCM I-2334),
A recombinant host cell able to secrete at least one BSH.

Assignees

• Agronomique Inst Nat Rech
• Museum Nat D'Histoire Naturelle
• Ecole Nat Veterinaire D'Alfort

Inventors

• Bermudez-Humaran Luis G
• Allain Thibault
• Florent Isabelle
• Langella Philippe
• Grellier Philippe
• Travers Marie-Agnes
• Polack Bruno

Classifications

• A61P33/02

  Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis · CPC title

• H03K2217/960745

  Capacitive differential; e.g. comparison with reference capacitance · CPC title

• H03K17/955

  using a capacitive detector · CPC title

• H03K2217/96075

  involving bridge circuit · CPC title

• A61K38/164

  from bacteria · CPC title